ACELYRIN
SLRN
SLRN was delisted on the 21st of May, 2025.
82 hedge funds and large institutions have $1.6B invested in ACELYRIN in 2023 Q2 according to their latest regulatory filings, with 82 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3,526% more call options, than puts
Call options by funds: $2.79M | Put options by funds: $77K
79.39% more ownership
Funds ownership: 0% → 79.39% (+79%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$152M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$124M |
| 3 |
O
OrbiMed
New York
|
+$109M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$85.1M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
+$78.9M |
Top Sellers
SLRN Hedge Fund Activity: Q2 2023 in Review
82 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q2 2023, worth a combined $1.6B.
Buyers outnumbered sellers: 82 funds opened new SLRN positions and 0 closed out — a net gain of 82 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $152M.
- 82 institutional investors held ACELYRIN (SLRN) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $1.6B of ACELYRIN stock for Q2 2023.
- 82 funds opened new ACELYRIN positions in Q2 2023 and 0 closed out, a net change of +82 holders.
- The largest ACELYRIN buyer in Q2 2023 was Fidelity Investments, an estimated $152M added.
Based on aggregated 13F filings for Q2 2023.